Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Residents of Ensley now have a new resource for receiving free medical care, thanks to a new initiative by Alabama Regional ...